Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Marrelli

Showing results (151-160 of 223) with videos related to

Pageof 23
Sort By:
Cancers|April 13, 2024
Posterior and Para-Aortic (D2plus) Lymphadenectomy after Neoadjuvant/Conversion Therapy for Locally Advanced/Oligometastatic Gastric CancerDaniele Marrelli, Stefania Angela Piccioni, Ludovico Carbone, et al.
Annals of Surgical Oncology|July 5, 2022
Prediction of Metachronous Peritoneal Metastases After Radical Surgery for Colon Cancer: A Scoring System Obtained from an International Multicenter CohortCorrado Pedrazzani, Giulia Turri, Daniele Marrelli, et al.
Anti-Cancer Drugs|December 19, 2019
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancerRoberto Petrioli, Edoardo Francini, Sara Cherri, et al.
American Journal of Surgery|September 12, 2024
Weighing the benefits: Exploring the differential effects of light-weight and heavy-weight polypropylene meshes in inguinal hernia repair in a retrospective cohort studyNatale Calomino, Gianmario Edoardo Poto, Ludovico Carbone, et al.
European Radiology Experimental|October 8, 2025
Improved detection and quantification of peritoneal metastases using delayed contrast-enhanced dual-energy CT scansGiulio Bagnacci, Armando Perrella, Nunzia Di Meglio, et al.
Surgical Oncology|November 1, 2019
Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancerRoberto Petrioli, Daniele Marrelli, Franco Roviello, et al.
Annals of Surgical Oncology|June 3, 2023
Bidirectional Approach with PIPAC and Systemic Chemotherapy for Patients with Synchronous Gastric Cancer Peritoneal Metastases (GCPM)Francesco Casella, Maria Bencivenga, Giorgio Brancato, et al.
Frontiers in Oncology|June 20, 2022
The Percentage of Signet Ring Cells Is Inversely Related to Aggressive Behavior and Poor Prognosis in Mixed-Type Gastric CancerLuigi Marano, Maria Raffaella Ambrosio, Luca Resca, et al.
International Journal of Surgery (London, England)|September 18, 2021
Validating a nodal regression system for gastric cancer: An ancillary cohort study of the GASTRODOC trialLuca Saragoni, Leonardo Solaini, Daniele Marrelli, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|July 1, 2025
Impact of HER2 and microsatellite instability status on response to neoadjuvant/conversion therapy and survival in patients with gastric cancerStefania Angela Piccioni, Maurizio Costantini, Roberto Petrioli, et al.
Pageof 23

Showing results (151-160 of 223) with videos related to

Sort By:
Pageof 23
Cancers|April 13, 2024
Posterior and Para-Aortic (D2plus) Lymphadenectomy after Neoadjuvant/Conversion Therapy for Locally Advanced/Oligometastatic Gastric CancerDaniele Marrelli, Stefania Angela Piccioni, Ludovico Carbone, et al.
Annals of Surgical Oncology|July 5, 2022
Prediction of Metachronous Peritoneal Metastases After Radical Surgery for Colon Cancer: A Scoring System Obtained from an International Multicenter CohortCorrado Pedrazzani, Giulia Turri, Daniele Marrelli, et al.
Anti-Cancer Drugs|December 19, 2019
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancerRoberto Petrioli, Edoardo Francini, Sara Cherri, et al.
American Journal of Surgery|September 12, 2024
Weighing the benefits: Exploring the differential effects of light-weight and heavy-weight polypropylene meshes in inguinal hernia repair in a retrospective cohort studyNatale Calomino, Gianmario Edoardo Poto, Ludovico Carbone, et al.
European Radiology Experimental|October 8, 2025
Improved detection and quantification of peritoneal metastases using delayed contrast-enhanced dual-energy CT scansGiulio Bagnacci, Armando Perrella, Nunzia Di Meglio, et al.
Surgical Oncology|November 1, 2019
Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancerRoberto Petrioli, Daniele Marrelli, Franco Roviello, et al.
Annals of Surgical Oncology|June 3, 2023
Bidirectional Approach with PIPAC and Systemic Chemotherapy for Patients with Synchronous Gastric Cancer Peritoneal Metastases (GCPM)Francesco Casella, Maria Bencivenga, Giorgio Brancato, et al.
Frontiers in Oncology|June 20, 2022
The Percentage of Signet Ring Cells Is Inversely Related to Aggressive Behavior and Poor Prognosis in Mixed-Type Gastric CancerLuigi Marano, Maria Raffaella Ambrosio, Luca Resca, et al.
International Journal of Surgery (London, England)|September 18, 2021
Validating a nodal regression system for gastric cancer: An ancillary cohort study of the GASTRODOC trialLuca Saragoni, Leonardo Solaini, Daniele Marrelli, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|July 1, 2025
Impact of HER2 and microsatellite instability status on response to neoadjuvant/conversion therapy and survival in patients with gastric cancerStefania Angela Piccioni, Maurizio Costantini, Roberto Petrioli, et al.
Pageof 23